XLO logo

XILIO THERAPEUTICS INC

XLONASDAQ
🏆 #4283 by market capUS Equity
$8.01—
Last available close · quote unavailable
🔔
Track XLO
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▼ 3.8%
14d▼ 14.5%
30d▼ 10.9%
ytd▼ 11.1%
1y▼ 29.1%
🏦Market Cap
$50M
Small Cap
📈Revenue Growth (YoY)
327.3%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
0.8x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$6.47 – $12.58
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
6.6M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$44M
Last Q Revenue
$19M
P/E Ratio
—
P/S Ratio
0.8x
EPS (TTM)
$-1.54
Dividend Yield
—
Dilution (1yr)
+177.6%
XLO logo

XILIO THERAPEUTICS INC

XLO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$44M▲ +589.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.5%▼ −3.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$42M▼ −30.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −70.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.8M▲ +177.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$131M▲ +$83M YoY
StockOtter · stockotter.space

About XILIO THERAPEUTICS INC

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
5 analysts
Strong Buy2
Buy2
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.